Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2008 1
2009 1
2012 2
2013 1
2014 1
2016 1
2017 2
2018 1
2019 2
2020 4
2021 6
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Carrillo-Cruz E, Bilbao-Sieyro C, Prados de la Torre E, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua JM, Algarra L, Tormo M, Martínez-Sánchez P, Soria E, Serrano J, Alonso-Domínguez JM, García-Boyero R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez-Casares MT, Sánchez-García J, Barragán E, Montesinos P, On Behalf Of Pethema Group. Sargas C, et al. Among authors: garcia boyero r. Cancers (Basel). 2023 Jan 10;15(2):438. doi: 10.3390/cancers15020438. Cancers (Basel). 2023. PMID: 36672386 Free PMC article.
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.
Martínez-Cuadrón D, Megías-Vericat JE, Gil C, Bernal T, Tormo M, Martínez-Sánchez P, Rodríguez-Medina C, Serrano J, Herrera P, Simón JAP, Sayas MJ, Bergua J, Lavilla-Rubira E, Amigo ML, Benavente C, Lorenzo JLL, Pérez-Encinas MM, Vidriales MB, Colorado M, De Rueda B, García-Boyero R, Marini S, García-Suárez J, López-Pavía M, Gómez-Roncero MI, Noriega V, López A, Labrador J, Cabello A, Sossa C, Algarra L, Stevenazzi M, Solana-Altabella A, Boluda B, Montesinos P. Martínez-Cuadrón D, et al. Among authors: garcia boyero r. Haematologica. 2024 Jan 1;109(1):115-128. doi: 10.3324/haematol.2022.282506. Haematologica. 2024. PMID: 37199127 Free PMC article.
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, Martínez-Sánchez P, Rodríguez-Arbolí E, Gil C, Aguiar E, Bergua J, López-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodríguez-Medina C, López-Pavía M, Tormo M, Algarra L, Amigo ML, Sayas MJ, Labrador J, Rodríguez-Gutiérrez JI, Benavente C, Costilla-Barriga L, García-Boyero R, Lavilla-Rubira E, Vives S, Herrera P, García-Belmonte D, Herráez MM, Vasconcelos Esteves G, Gómez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MÁ, Montesinos P. Martínez-Cuadrón D, et al. Among authors: garcia boyero r. Blood Adv. 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335. Blood Adv. 2022. PMID: 34794172 Free PMC article. Clinical Trial.
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, Barba P, Ribera J, García-Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, González-Campos J, Rodríguez C, Bermúdez A, Novo A, Soria B, Coll R, Amigo ML, López-Martínez A, Fernández-Martín R, Serrano J, Mercadal S, Cladera A, Giménez-Conca A, Peñarrubia MJ, Abella E, Vall-Llovera F, Hernández-Rivas JM, Garcia-Guiñon A, Bergua JM, de Rueda B, Sánchez-Sánchez MJ, Serrano A, Calbacho M, Alonso N, Méndez-Sánchez JÁ, García-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Ribera JM, et al. Among authors: garcia boyero r. Blood. 2021 Apr 8;137(14):1879-1894. doi: 10.1182/blood.2020007311. Blood. 2021. PMID: 33150388 Free article. Clinical Trial.
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.
Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, García-Cadenas I, de Llano MPQ, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, Garcia-Boyero R, Novo A, Hernandez Rivas JM, Cladera A, Martinez-Sanchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, Ribera JM. Barba P, et al. Among authors: garcia boyero r. Hemasphere. 2022 Dec 23;7(1):e810. doi: 10.1097/HS9.0000000000000810. eCollection 2023 Jan. Hemasphere. 2022. PMID: 36583094 Free PMC article. No abstract available.
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Martínez-Cuadrón D, Serrano J, Mariz J, Gil C, Tormo M, Martínez-Sánchez P, Rodríguez-Arbolí E, García-Boyero R, Rodríguez-Medina C, Martínez-Chamorro C, Polo M, Bergua J, Aguiar E, Amigo ML, Herrera P, Alonso-Domínguez JM, Bernal T, Espadana A, Sayas MJ, Algarra L, Vidriales MB, Vasconcelos G, Vives S, Pérez-Encinas MM, López A, Noriega V, García-Fortes M, Chillón MC, Rodríguez-Gutiérrez JI, Calasanz MJ, Labrador J, López JA, Boluda B, Rodríguez-Veiga R, Martínez-López J, Barragán E, Sanz MA, Montesinos P, On Behalf Of The Pethema Group. Martínez-Cuadrón D, et al. Among authors: garcia boyero r. Cancers (Basel). 2022 Jun 6;14(11):2817. doi: 10.3390/cancers14112817. Cancers (Basel). 2022. PMID: 35681796 Free PMC article.
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castaño-Bonilla T, Barragán E, Sargas C, Sanz A, Algarra L, Herrera-Puente P, García-Boyero R, Barrios M, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Serrano-López J, Martínez-López J, Sayas-Lloris MJ, Olave MT, Riaza-Grau R, Castillo TB, Larrayoz MJ, Amigo R, Jiménez-Velasco A, Sánchez J, Ayala R, Blas C, Lainez D, Serrano-López J, Sanz MA, Alonso-Domínguez JM, Montesinos P. Castaño-Bonilla T, et al. Among authors: garcia boyero r. Dis Markers. 2022 Aug 23;2022:3132941. doi: 10.1155/2022/3132941. eCollection 2022. Dis Markers. 2022. PMID: 36051360 Free PMC article.
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Martínez-Cuadrón D, Serrano J, Gil C, Tormo M, Martínez-Sánchez P, Pérez-Simón JA, García-Boyero R, Rodríguez-Medina C, López-Pavía M, Benavente C, Bergua J, Lavilla-Rubira E, Amigo ML, Herrera P, Alonso-Domínguez JM, Bernal T, Colorado M, Sayas MJ, Algarra L, Vidriales MB, Rodríguez-Macías G, Vives S, Pérez-Encinas MM, López A, Noriega V, García-Fortes M, Ramos F, Rodríguez-Gutiérrez JI, Costilla-Barriga L, Labrador J, Boluda B, Rodríguez-Veiga R, Martínez-López J, Sanz MA, Montesinos P. Martínez-Cuadrón D, et al. Among authors: garcia boyero r. Leukemia. 2021 Jun;35(6):1571-1585. doi: 10.1038/s41375-020-01058-4. Epub 2020 Oct 19. Leukemia. 2021. PMID: 33077867
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
Salamero O, Martínez-Cuadrón D, Sobas M, Benavente C, Vives S, De la Serna J, Pérez-Encinas M, Escoda L, Gil C, Brunet S, Ramos F, Esteve J, Amigo M, Krsnik I, Manso F, Arias J, González-Campos J, Serrano J, Oleksiuk J, Barrios M, García-Boyero R, Novo A, Sanz MA, Montesinos P; PETHEMA and PALG Groups. Salamero O, et al. Among authors: garcia boyero r. Leuk Lymphoma. 2019 Nov;60(11):2720-2732. doi: 10.1080/10428194.2019.1607327. Epub 2019 May 9. Leuk Lymphoma. 2019. PMID: 31068052
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández-Campo P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P; Spanish PETHEMA group. Martínez-Cuadrón D, et al. Among authors: garcia boyero r. Leuk Res. 2019 Jan;76:1-10. doi: 10.1016/j.leukres.2018.11.006. Epub 2018 Nov 13. Leuk Res. 2019. PMID: 30468991 Free article.
28 results